Learn about Activase® (alteplase) treatment for acute ischemic stroke (AIS). See full safety for more information. Indications Activase (alteplase) is indicated for. Contraindications: Cathflo Activase should not be administered to patients with by a suture and lipid deposits or drug precipitates within the catheter lumen). Activase® (Alteplase) is a tissue plasminogen activator produced by recombinant .. A study of another alteplase product, Actilyse, in acute ischemic stroke, . mg vial—insert the spike end of an infusion set through the same puncture site.
|Published (Last):||9 August 2010|
|PDF File Size:||15.24 Mb|
|ePub File Size:||4.69 Mb|
|Price:||Free* [*Free Regsitration Required]|
Assess catheter function after 30 minutes of dwell time by attempting to aspirate blood; if unable to aspirate after minutes dwell time, a 2nd dose may be administered and the process repeated. Your email activase package insert been sent!
Thrombolytic of Choice in Stroke? There are no adequate and well-controlled studies in pregnant women. Do not use in pregnancy. Print without Office Info. Activase package insert would you like to print? Such force could cause rupture of the catheter or expulsion of the clot into the circulation. Acute Ischemic Stroke 0. View explanations for tiers activase package insert restrictions. This drug is available at a middle level co-pay. Significant – Monitor Closely.
You may also report side effects to Genentech at Create Your List of Plans.
Cathflo Activase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. This drug is available at a higher level co-pay. Sign Up It’s Free! Submit the form below to share this with a friend or colleague.
Use only the accompanying sterile water for injection activase package insert packaye ; do not use bacteriostatic water for injection.
Brand and Other Names: Remove the protective cap from 1 end of the transfer device and keeping the vial of SWFI upright, insert the piercing pin vertically into the center of the stopper of the vial of SWFI 5. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. Monitor patients treated with Cathflo Activase for activase package insert of hypersensitivity and treat appropriately if necessary. Contraindications Cathflo Activase should not be administered to patients with known hypersensitivity to alteplase or any component of the formulation.
Most commonly, these are “non-preferred” brand drugs. Should serious bleeding in insret activase package insert location e.
If catheter function restored, aspirate mL blood to remove Cathflo Activase and residual clot. Individual paclage may vary and formulary information changes. View videos and instructions for the recommended dosing and administration of Cathflo. activase package insert
This restriction typically requires that certain criteria be met prior to approval for the prescription. All fields are required. Indert Activase preparation Reconstitute 2 mg vial by adding 2. Inspect parenteral drug activase package insert for particulate matter and discoloration prior to administration whenever solution and container permit. Print this section Print the entire contents of.
FDA Internet Application Site (Accessdata) Error
To view formulary information activase package insert create a list of plans. Recommended total dose for AMI is based on patient weight, not to exceed mg, regardless of the selected administration packagw accelerated or 3 hr. Print with Activase package insert Info. Click “OK” if you are a healthcare professional. Bleeding The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding.
Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter. If you log out, you will be required to enter your username and password the next time you visit. The information contained in this section of the site is intended for U. Cathflo Activase should not be administered to patients with known hypersensitivity to alteplase or any component of the formulation.
Published studies and case reports on alteplase use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes; alteplase is embryocidal in rabbits when intravenously administered during organogenesis at activase package insert exposure for AMI, but no maternal or fetal toxicity activase package insert evident at lower exposure activase package insert pregnant rats or rabbits; the most common complication of thrombolytic therapy is bleeding; pregnancy may increase this risk; drug should be used during pregnancy only if potential benefit justifies potential risk to fetus.
Share cases and questions with Physicians on Medscape consult.
Single-Use Vial Lytic Thrombolytic – Cathflo® Activase® (alteplase)
Your list will be saved and can be edited at any time. The interaction of Cathflo Activase with activase package insert drugs has not been formally studied.
Risks involved outweigh potential benefits. Quantity Limits Drugs that have quantity limits associated with packagd prescription. Controlled studies in pregnant women show no evidence of fetal risk.
This restriction typically limits the quantity of the drug that will be covered. Formulary Formulary Activase package insert Discounts. Animal studies show risk and human studies not activase package insert or neither animal nor human studies done. If arterial puncture necessary during therapy infusion, use upper extremity vessel that is accessible to manual compression, apply pressure for at least 30 min, and monitor puncture site closely.
Use aseptic technique 2. Lactation There are no data on presence of alteplase in human milk, effects on breastfed infant, or on milk production.